141 related articles for article (PubMed ID: 31246934)
1. Interventions to Prevent Nonmelanoma Skin Cancers in Recipients of a Solid Organ Transplant: Systematic Review of Randomized Controlled Trials.
Chung EYM; Palmer SC; Strippoli GFM
Transplantation; 2019 Jun; 103(6):1206-1215. PubMed ID: 31246934
[TBL] [Abstract][Full Text] [Related]
2. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials.
Chen K; Craig JC; Shumack S
Br J Dermatol; 2005 Mar; 152(3):518-23. PubMed ID: 15787821
[TBL] [Abstract][Full Text] [Related]
3. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients.
Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R
J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579
[TBL] [Abstract][Full Text] [Related]
4. Local interventions for actinic keratosis in organ transplant recipients: a systematic review.
Heppt MV; Steeb T; Niesert AC; Zacher M; Leiter U; Garbe C; Berking C
Br J Dermatol; 2019 Jan; 180(1):43-50. PubMed ID: 30188570
[TBL] [Abstract][Full Text] [Related]
5. Behavioural and pharmaceutical interventions for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomised controlled trials.
James LJ; Saglimbene V; Wong G; Tong A; Luu LDW; Craig J; Howard K; Howell M
BMJ Open; 2020 May; 10(5):e029265. PubMed ID: 32423925
[TBL] [Abstract][Full Text] [Related]
6. Topical tacrolimus for atopic dermatitis.
Cury Martins J; Martins C; Aoki V; Gois AF; Ishii HA; da Silva EM
Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD009864. PubMed ID: 26132597
[TBL] [Abstract][Full Text] [Related]
7. Cancer and mTOR Inhibitors in Transplant Recipients.
de Fijter JW
Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients.
Fairfield C; Penninga L; Powell J; Harrison EM; Wigmore SJ
Cochrane Database Syst Rev; 2015 Dec; (12):CD007606. PubMed ID: 26666504
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
Penninga L; Wettergren A; Chan AW; Steinbrüchel DA; Gluud C
Cochrane Database Syst Rev; 2012 Mar; (3):CD008852. PubMed ID: 22419339
[TBL] [Abstract][Full Text] [Related]
10. Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?
Jung JW; Overgaard NH; Burke MT; Isbel N; Frazer IH; Simpson F; Wells JW
Int J Cancer; 2016 Jan; 138(2):281-92. PubMed ID: 25612559
[TBL] [Abstract][Full Text] [Related]
11. Immunosuppressive T-cell antibody induction for heart transplant recipients.
Penninga L; Møller CH; Gustafsson F; Gluud C; Steinbrüchel DA
Cochrane Database Syst Rev; 2013 Dec; (12):CD008842. PubMed ID: 24297433
[TBL] [Abstract][Full Text] [Related]
12. Nonmelanoma skin cancer after kidney transplant.
Tepeoğlu M; Ayva Ş; Ok Atılgan A; Tunca MZ; Özdemir BH; Moray G; Yıldırım S; Arslan G; Haberal M
Exp Clin Transplant; 2014 Jun; 12(3):233-7. PubMed ID: 24907724
[TBL] [Abstract][Full Text] [Related]
13. Skin Cancer Risk Awareness and Sun-Protective Behavior Among Solid-Organ Transplant Recipients.
Tunçer Vural A; Karataş Toğral A; Kırnap M; Güleç AT; Haberal M
Exp Clin Transplant; 2018 Mar; 16 Suppl 1(Suppl 1):203-207. PubMed ID: 29528028
[TBL] [Abstract][Full Text] [Related]
14. Use of Topical and Systemic Retinoids in Solid Organ Transplant Recipients: Update and Review of the Current Literature.
Herold M; Good AJ; Nielson CB; Longo MI
Dermatol Surg; 2019 Dec; 45(12):1442-1449. PubMed ID: 31403546
[TBL] [Abstract][Full Text] [Related]
15. Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients.
Funk-Debleds P; Ducroux E; Guillaud O; Ursic-Bedoya J; Decullier E; Vallin M; Euvrard S; Pageaux GP; Boillot O; Dumortier J
J Am Acad Dermatol; 2018 Jul; 79(1):84-91. PubMed ID: 29307647
[TBL] [Abstract][Full Text] [Related]
16. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
17. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients.
Ulrich C; Schmook T; Sachse MM; Sterry W; Stockfleth E
Dermatol Surg; 2004 Apr; 30(4 Pt 2):622-7. PubMed ID: 15061846
[TBL] [Abstract][Full Text] [Related]
18. The risk of cancer in kidney transplant recipients may be reduced in those maintained on everolimus and reduced cyclosporine.
Lim WH; Russ GR; Wong G; Pilmore H; Kanellis J; Chadban SJ
Kidney Int; 2017 Apr; 91(4):954-963. PubMed ID: 28109543
[TBL] [Abstract][Full Text] [Related]
19. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids.
Kreher MA; Noland MMB; Konda S; Longo MI; Valdes-Rodriguez R
J Am Acad Dermatol; 2023 Mar; 88(3):521-530. PubMed ID: 36460257
[TBL] [Abstract][Full Text] [Related]
20. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials.
Pengel LH; Liu LQ; Morris PJ
Transpl Int; 2011 Dec; 24(12):1216-30. PubMed ID: 21955006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
